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Abstract
BACKGROUND—The 5-year relative survival for prostate cancers diagnosed between 1990 and 
1994 in the United States was very high (92%); however, survival in black males was 7% lower 
compared with white males. The authors updated these findings and examined survival by stage 
and race.
METHODS—The authors used data from the CONCORD-2 study for males (ages 15–99 years) 
who were diagnosed with prostate cancer in 37 states, covering 80% of the US population. 
Survival was adjusted for background mortality (net survival) using state-specific and race-specific 
life tables and was age-standardized. Data were presented for 2001 through 2003 and 2004 
through 2009 to account for changes in collecting SEER Summary Stage 2000.
RESULTS—Among the 1,527,602 prostate cancers diagnosed between 2001 and 2009, the 
proportion of localized cases increased from 73% to 77% in black males and from 77% to 79% in 
white males. Although the proportion of distant-stage cases was higher among black males than 
among white males, they represented less than 6% of cases in both groups between 2004 and 
2009. Net survival exceeded 99% for localized stage between 2004 and 2009 in both racial groups. 
Overall, and in most states, 5-year net survival exceeded 95%.
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CONCLUSIONS—Prostate cancer survival has increased since the first CONCORD study, and 
the racial gap has narrowed. Earlier detection of localized cancers likely contributed to this 
finding. However, racial disparities also were observed in overall survival. To help understand 
which factors might contribute to the persistence of this disparity, states could use local data to 
explore sociodemographic characteristics, such as survivors’ health insurance status, health 
literacy, treatment decision-making processes, and treatment preferences.
Keywords
cancer registries; early detection of cancer; population-based survival; prevention and control; 
prostate cancer; Surveillance; Epidemiology; and End Results (SEER) summary stage; 
therapeutics; trends
INTRODUCTION
Prostate cancer is the second most commonly diagnosed cancer in males worldwide and, in 
the United States, the most commonly diagnosed invasive cancer in males.1,2 Prostate cancer 
is also the fifth leading cancer-related cause of death worldwide and, in the United States, 
the second leading cause of cancer death among males.1–3 In the United States, black males 
have higher incidence and death rates than white males.2,3 Worldwide, black males have 
higher prostate cancer incidence and death rates than other males.1 In the United States, the 
incidence of prostate cancer increased rapidly in the early1990s after widespread adoption of 
prostate cancer screening using the prostate-specific antigen (PSA) test, peaked in the early 
1990s, and then declined sharply thereafter; the decline has been more gradual since 
2000.4–6 Prostate cancer death rates increased through the early 1990s and have been 
gradually declining since the mid-1990s among both white and black males.6
The first CONCORD study provided a systematic comparison of survival for males (ages 
15–99 years) who were diagnosed with prostate cancer in 31 countries between 1990 and 
1994 and were followed until 1999.7 Data for the United States were included from 21 state-
wide and metropolitan-area cancer registries covering 42% of the US population. 
International differences in age-standardized prostate cancer survival were wide, even after 
adjustment for differences in mortality from other causes of death, with prostate cancer 
survival highest in the United States compared with other countries. Five-year survival was 
higher for white males (92.4%) compared with black males (85.8%) in the United States. 
This may reflect disparities in the receipt of standard care as well as differences in stage at 
diagnosis.
The second CONCORD study (CONCORD-2) was undertaken, in part, to update findings 
from the first CONCORD study and to allow for a more in-depth examination of cancer 
survival by race and stage.8 For the current study, we used CONCORD-2 data to examine 
cross-state trends in prostate cancer survival up to 5 years among black and white males by 
cancer stage.
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MATERIALS AND METHODS
Data Source
We used data from 37 state-wide cancer registries that participated in the CONCORD-2 
study8 and consented to the inclusion of their data in the more detailed analyses reported 
here. We analyzed individual tumor records for males (ages 15–99 years) who were 
diagnosed with prostate cancer between 2001 and 2009 and were followed through 
December 31, 2009. Cases were identified using International Classification of Diseases for 
Oncology third edition topography code C61.9 (prostate) and behavior code 3 (malignant).9 
We included all cases of cancer originating in the prostate, regardless of a previous cancer 
diagnosis in the same individual.
Males were grouped by diagnosis year into 2 calendar periods (2001–2003 and 2004–2009) 
to reflect changes in the methods used by US cancer registries to collect data on stage at 
diagnosis. Between 2001 and 2003, most registries coded stage directly from medical 
records to the Surveillance, Epidemiology, and End Results (SEER) Summary Stage 2000 
(SS2000).10 Since 2004, all registries have derived SS2000 using the Collaborative Staging 
System.11
Survival Analyses
We estimated net survival up to 5 years after diagnosis and 95% confidence intervals (CIs) 
using the Pohar Perme estimator.12 Net survival is the probability of survival up to a given 
time since diagnosis, after controlling for other causes of death (background mortality). To 
control for wide differences in background mortality among participating states, we used a 
flexible Poisson model to construct life tables of all-cause mortality in the general 
population of each state from the number of deaths and the population, by single year of age, 
sex, calendar year, and, where possible, by race (all, black, white).13 Methods for 
constructing life tables have been published.14
We estimated net survival using the cohort approach for patients diagnosed between 2001 
and 2003, because all patients had been followed for at least 5 years by December 31, 2009. 
We used the complete approach to estimate net survival for patients diagnosed between 2004 
and 2009, because 5 years of follow-up data were not available for all patients. We obtained 
age-standardized survival estimates using International Cancer Survival Standard weights.15 
Unstandardized estimates are italicized in the supporting tables. Trends, geographic 
variations, and differences in age-standardized survival by race are presented graphically in 
bar charts and funnel plots.16 The funnel plots provide insight into the variability of cancer 
survival in the United States by race and state and illustrate how much a particular survival 
estimate deviates from the pooled estimate of US registries, given the precision of each 
estimate. For additional details on the methods and data quality for this study, see the article 
by Allemani et al in this Supplement.8
RESULTS
In total, 1,527,602 males with prostate cancer were eligible for analysis, of whom 81.3% 
were white, and 13.7% were black. The pooled results from the 37 US registries are 
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provided in Tables (1 and 2), and 3; and state-specific results are reported in Supporting 
Tables 1, 2, and 3. Table 1 details the distribution of SS2000 by race and calendar period.
In the pooled estimate, the distributions of males diagnosed with localized, regional, and 
distant prostate cancer were similar during both calendar periods. Between the periods from 
2001 to 2003 and from 2004 to 2009, the proportions of cases diagnosed at localized stage 
increased from 72.8% to 76.8% among black males and from 77.2% to 78.8% among white 
males. More black males than white males were diagnosed with distant stage prostate cancer 
between 2001 and 2003 (5.7% vs 3.5%) and between 2004 and 2009 (5.2% vs 3.5%). 
Similar patterns in the distribution of stage by race were observed in the states during both 
calendar periods (Supporting Table 1).
Table 2 presents 1-year, 3-year, and 5-year survival estimates by race and calendar period. 
Overall, survival did not change between the 2 calendar periods. Net survival estimates 
among males who were diagnosed between 2001 and 2003 were 98.6% at 1 year, 97.4% at 3 
years, and 96.7% at 5 years; corresponding estimates among males who were diagnosed 
between 2004 and 2009 were 98.8%, 97.6%, and 96.9%, respectively. White males had 
higher 1-year, 3-year, and 5-year net survival than black males. This pattern held true in 
most states (Supporting Table 2).
Table 3 displays 5-year net survival estimates by race and stage. The pooled estimates for the 
US registries were comparable between black and white males for localized, regional, and 
distant prostate cancer during both calendar periods. Between 2004 and 2009, survival 
exceeded 99% for localized stage and less than 29% for distant stage in both racial groups. 
However, corresponding estimates varied across the states (Supporting Table 3).
During both calendar periods, as illustrated in Figure 1, the age standardized, 5-year net 
survival estimates across most states were very high (≥95%) for all races combined. State-
specific differences in 5-year net survival were small between males diagnosed between 
2001 and 2003 and those diagnosed between 2004 and 2009. Racial and geographic 
differences in 5-year net survival are displayed graphically in funnel plots (Fig. 2). Survival 
among black males (Fig. 2, solid circles) was lower compared with that among white males 
(Fig. 2, open circles), and most estimates were below the pooled estimate. There was less 
variation around the pooled estimates among white males.
DISCUSSION
This study compared prostate cancer stage distribution and survival estimates by race among 
males who were diagnosed between 2001 and 2003 and between 2004 and 2009 in 37 states, 
covering 80% of the US population. We observed high percentages of localized prostate 
cancer among black and white males diagnosed during both calendar periods, whereas black 
males had slightly higher proportions of distant disease at diagnosis compared with white 
males. Overall, there was no change in net survival between the 2 calendar periods in either 
racial group. The high but stable survival estimates in our analysis might reflect trends in 
prostate cancer incidence, rather than true improvements in survival. The incidence of 
prostate cancer increased rapidly between the 1980s and the 1990s, largely because of the 
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widespread use of PSA-based screening.17 The increase in incidence was followed by a 
steady decline in the late 1990s, as the pool of prevalent cases available for detection 
decreased.18–20 It has been reported that the declines in incidence of localized/regional 
prostate cancer and of distant prostate cancer started in 2001 and 1995, respectively.17 
Another study noted that most decreases in prostate cancer incidence since 2008 have 
occurred uniformly across age and racial/ethnic groups among males diagnosed at the 
localized/regional stage.20 Similar to prostate cancer incidence, prostate cancer mortality 
rates started to decrease in the 1990s.3,18,21–23 The decline has been attributed to several 
different factors, including PSA screening intensity and improvements in treatment of 
distant-stage disease.18,21–23
Five-year net survival among black and white males who were diagnosed with localized/
regional prostate cancer between 2001 and 2009 approached 99% overall and in most states. 
Previous studies have reported that racial disparities in prostate cancer survival among males 
diagnosed at these stages have decreased over time.24–26 During both calendar periods, we 
observed that 5-year net survival for all other stages was also comparable among black and 
white males. Across the states, there was more variation in survival among males diagnosed 
at distant stage than among those diagnosed at other stages; however, these estimates were 
based on small numbers. State-specific variation in cancer survival might be related to 
differences in the demographic characteristics of males at risk for prostate cancer, in 
spending on cancer prevention and control, and in health insurance coverage rates.27–29
The very high 5-year prostate cancer survival that we observed among US males has also 
been reported among males in several European countries.8 Survival increased in many of 
these countries between the periods from 1995 to 1999 and from 2005 to 2009; however, 
increases were smaller in North America, where survival has been very high since the early 
1990s.
Clinical Implications
Although adoption of PSA-based prostate cancer screening in the United States over the past 
2 decades has led to diagnosis of prostate cancer at earlier stages and improved survival, it 
has also resulted in overdiagnosis (ie, detection in individuals who would have died of other 
causes) and over-treatment of many clinically insignificant tumors.30,31 Therefore, as 
concerns about potential harms of PSA-based screening emerged, some organizations and 
professional societies recommended against screening males of all ages; however, others 
emphasized shared decision making and age-specific testing.32–37 Strategies to help 
clinicians reduce these problems have included updating prostate cancer screening 
recommendations and using prediction tools to help improve risk stratification.38–40 Tools in 
use or development to improve clinical stratification for screening and treatment include 
biomarkers, nomograms, genomic testing, and enhanced imaging.39,40 Increased use of 
active surveillance for males diagnosed with localized prostate cancer might also relieve 
some of the burdens associated with early intervention.38
Findings regarding the effect of widespread PSA screening on prostate cancer mortality have 
been mixed. Some studies have reported that testing reduces the number of deaths from the 
disease, but others did not report an association.21,41–43 The age-adjusted annual death rate 
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from prostate cancer among black males is 2 to 3 times that of white males, which is caused 
in part by their higher disease incidence, tumor characteristics, treatment choices, and 
socioeconomic status.2,44 Deaths have been declining since 1996 at a rate of 3.6% per year 
among black males and 3.4% among white males.26 However, the reasons for the persistence 
of the racial disparity are not clear.
Changes in clinical management of prostate cancer in the United States over the past 3 
decades also may have affected survival. A dramatic increase in the receipt of radical 
prostatectomy overall was reported from the mid-1980s, followed by a plateau in the early 
1990s; the rate started to increase again in the early 2000s, but the increase was gradual.21 
Among males with small, low-grade, clinical stage T3 (ie, locally advanced) prostate cancer, 
an increase in the receipt of surgery was reported between 1998 and 2012.45 One study 
reported that surgery receipt declined between 1995 and 2013 among males with low-risk 
prostate cancer, whereas it increased among those with intermediate-risk prostate cancer and 
among older males with low-risk and intermediate-risk disease.46 In another study, however, 
receipt of radical prostatectomy increased between 2004 and 2010 among males with low-
risk and intermediate-risk prostate cancer.47
Demographic disparities have been reported in the receipt of definitive treatment for prostate 
cancer, with lower rates among black males and variations by insurance type, geographic 
region, and age group.29,48–55 Differences in treatment preferences may account for some of 
these disparities. In earlier research examining treatment choice among males with localized 
prostate cancer, black males reportedly were more likely to select nonsurgical options 
compared with their white counterparts.49,56,57 A more recent study indicated that, although 
active surveillance was the most preferred treatment among black and white males with 
localized prostate cancer, surgery was more common among black males.58 The treatment 
decision-making process also may differ by race/ethnicity and by other sociodemographic 
factors. In 1 study of males with localized prostate cancer, white males selected active 
surveillance/watchful waiting based on cancer risk, but black males did not; this raises 
concerns about under-treatment and lack of understanding about cancer risk among the latter 
group.53 A study of treatment choice among males in urban and rural parts of Georgia 
reported that disparities may be related more to differences in income than differences in 
race.55 The authors also noted, however, that poor communication with physicians was more 
prevalent among black patients and was associated with not receiving treatment in rural 
areas.
Cancer-Control Implications
Monitoring disparities in prostate cancer survival, especially with survival rates for distant 
stage, requires high-quality surveillance data. To more comprehensively define these 
disparities, the data could be enhanced with information about socioeconomic factors and 
other social determinants of health that affect cancer outcomes.59 Lack of insurance, low 
educational attainment, and poverty status are all associated with increased cancer risk and 
poor outcomes.25,27,29,50 To help assess prostate cancer outcomes across the states, cancer-
control practitioners could continue to work with programs like the Centers for Disease 
Control and Prevention’s (CDC’s) National Program of Cancer Registries (NPCR) and 
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National Comprehensive Cancer Control Program.60 Other CDC resources available to 
cancer-control planners include communication materials that explore clinician-patient 
discussions about prostate cancer screening and treatment, research that has examined 
enhancement of prostate cancer data in cancer registries and patterns of prostate cancer care, 
and findings from an active surveillance state-of-science consensus conference organized by 
the agency. In addition, the CDC has supported projects to explore patient information-
seeking behavior postdiagnosis, caregiver and provider involvement in treatment decision 
making, and patient quality of life after prostate cancer treatment.61 To help reduce 
disparities in receipt of prostate cancer treatment, cancer-control planners could examine 
these factors and others, such as patient comorbidities and provider characteristics. They 
also might assess whether disparities in post-treatment care affect long-term and late effects 
that prostate cancer survivors may experience.
The current study has notable strengths. The CONCORD-2 study is the largest comparative 
study of population-based cancer survival in the United States, and it includes high-quality 
data covering 80% of the US population. Standardized collection, reporting, and analysis of 
the data ensures the availability of comparable data. A high percentage (>97%) of cases in 
the United States are microscopically confirmed, and the percentage of cases with unknown 
stage (11.1% in 2001–2003, 8.4% in 2004–2009) is relatively low.8
However, this study has a few limitations, which might influence interpretation of the 
results. First, follow-up procedures among cancer registries in the United States differ, 
depending on federal funding source.60 All SEER registries are required to conduct active 
follow-up of all registered cases to ascertain vital status. NPCR registries are only funded to 
ascertain deaths through linkages with state vital records and the National Death Index; 
therefore, they may overestimate survival time and miss some deaths, because death 
ascertainment is conducted primarily through data linkages.62 Second, the manner in which 
SS2000 data were collected and reported changed for all registries in 2004, as described 
above (see Materials and Methods). The impact of this change was most evident in NPCR-
funded registries, where the percentage of cases with unknown stage decreased somewhat 
when stage was derived rather than manually coded.
Conclusions
Prostate cancer survival remains high among males whose disease is detected early, and the 
racial gap in survival observed in the first CONCORD study has narrowed. Disparities in 
receipt of standard and timely care are still being reported, however, particularly among 
males who might benefit most from treatment.48–52,54 To help ensure that all prostate cancer 
survivors receive appropriate care, cancer-control planners could optimize their use of local 
data and resources to explore demographic differences in survivors’ access to health 
insurance, primary and specialty medical care, and timely receipt of treatment. Clinicians 
should be aware that, although a recent study of males diagnosed with low-risk prostate 
cancer indicated that most patients were satisfied with their treatment decision-making 
discussions with physicians, a patient’s health literacy could affect his understanding of 
cancer risk and treatment options.58
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Prostate cancer 5-year, age-standardized net survival (%) for males (ages 15–99 years) 
diagnosed between 2001 and 2003 and between 2004 and 2009 and absolute change (%) are 
illustrated. States are grouped by US Census region. Note that data from 37 statewide cancer 
registries (covering 80.6% of the population) are ranked within US Census Region by the 
survival estimate for 2004 to 2009. Dark colors denote states affiliated with the National 
Program of Cancer Registries (NPCR), and pale colors denote states affiliated with the 
Surveillance, Epidemiology, and End Results (SEER) Program. An asterisk denotes states 
affiliated with both federal surveillance programs. Change (%) was not plotted if a survival 
estimate was not available for 1 calendar period or if 1 or more estimates were not age-
standardized.
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Figure 2. 
Prostate cancer 5-year, age-standardized net survival (%) is illustrated for males (ages 15–99 
years) by state, race, and calendar period of diagnosis. Note that the pooled US survival 
estimate for each calendar period is indicated by the horizontal (solid) line with 
corresponding 95.0% and 99.8% control limits (dashed lines).
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